ArticlePloS one2026
Preparation and application of Taq DNA polymerase monoclonal antibody guided by structural domain analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recombinant Thermostable DNA Polymerases: Current Approaches to Production, Molecular Engineering, and Applications in Biotechnology and Diagnostics.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hot-start polymerase chain reaction (hot-start PCR) effectively inhibits non-specific product amplification during PCR, with hot-start Taq DNA polymerase (HS Taq) serving as the critical component. Current HS Taq preparation methods, including chemical modification and aptamer-based approaches, exhibit limitations such as prolonged activation time, reduced enzyme activity, and inadequate blocking specificity. In contrast, antibody-mediated hot-start Taq offers distinct advantages: rapid activation, stable enzymatic performance, and high blocking specificity through targeted binding to functional domains. While antibody-based hot-start Taq DNA polymerases are widely utilized for their high efficiency and specificity, their development often relies on commercial sources or complex genetic engineering. This dependency constrains the independent and customizable development of core PCR components. To address this, our study established a streamlined platform for generating highly effective monoclonal antibodies that inhibit Taq enzyme activity. The key innovation lies in our structure-guided, domain-specific immunization strategy: instead of using the full-length enzyme, we targeted the polymerase domain (Taq-P) to generate a specific monoclonal antibody that acts as a reversible inhibitor. This approach overcomes the major challenge of generating functional antibodies against cryptic epitopes, which are poorly immunogenic in the full-length protein. This antibody sterically blocks the enzyme's active site at room temperature, preventing non-specific priming during PCR setup, and dissociates upon thermal activation to restore full activity. The resulting hot-start Taq enzyme significantly reduced non-specific amplification in quantitative PCR assays, and its practical utility was successfully demonstrated in detecting fungal pathogens and respiratory viruses using clinical samples. This study provides a feasible and effective strategy for the autonomous development of critical reagents for molecular diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.